<DOC>
	<DOCNO>NCT01430390</DOCNO>
	<brief_summary>The purpose study test safety give patient special cell donor call `` Modified T-cells '' . The goal find safe dose modify T-cells patient relapse B cell leukemia lymphoma blood SCT . The investigator also want find effect T-cells patient disease .</brief_summary>
	<brief_title>In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes ( EBV-CTLs ) Genetically Targeted CD19 Antigen B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>History CD19+ leukemia evidence bone marrow relapse persistent MRD follow allogenic hematopoietic stem cell transplantation . Bone marrow relapse protocol &gt; 5 % blast morphology and/or flow cytology . Persistent minimal residual disease transplantation must demonstrate morphology , FISH , flow cytometry RTPCR least 2 sequential testing separate least 1 week . History relapse refractory CD19+ malignancy ( e.g . Non Hodgkin Lymphoma ) fail prior treatment require autologous hematopoietic stem cell transplant . Evidence disease require . No age restriction patient KPS Lansky score &gt; = 40 Renal function ( measure prior condition chemotherapy ) Hepatic function ( measure prior condition chemotherapy ) : AST ≤ 5 x institutional ULN Elevation secondary leukemic involvement exclusion criterion . Leukemic involvement determine presence progressive relapse define escalate bone marrow peripheral blood leukemia blast within previous month absence initiation know hepatotoxic medication ( e.g . azoles ) . Total bilirubin ≤ 2.5 x institutional ULN Adequate cardiac function ( e.g . LVEF ≥ 40 % ) assess ECHO MUGA similar cardia imaging perform within 1 month enrollment . Pulmonary function ( measure prior condition chemotherapy ) : Oxygen saturation ≥ 90 % room air Donor Eligibility : The patient 's HSCT donor , HSCT donor available third party donor , must consent leukapheresis whole blood donation ( ) obtain one phlebotomy , aggregate , total approximately 250 ml adult 5ml/kg per draw pediatric donor . Related donor &lt; 18 year age require placement leukapheresis catheter donate peripheral blood collect phlebotomy ( include unit blood weight permit ) shall undergo catheter placement leukapheresis consider minimal risk donor . There upper age limit donor . However , minimum age relate donor 7 year youngest age person consider capable give assent participate research study . Evidence prior sensitization EBV EBV serology test ( seropositive ) Donor 's high resolution HLA typing must available review CBC within one week donation . Results test must within range would preclude donate blood undergoing leukapheresis . Serologic test transmissible disease perform per institutional guideline adopt extant NMDP FACT guideline . Donors consider eligible donate leukapheresis blood base guideline ( i.e . blood donation guideline ) Patients active HIV , hepatitis B hepatitis C infection . Patients concurrent active malignancy define malignancy require therapy expectant observation . Females pregnant . Patients exclude isolated extramedullary relapse ALL . Previous infusion CD19 CAR T cell another institution Patients active ( grade 24 ) acute graft versus host disease ( GVHD ) , chronic GVHD overt autoimmune disease ( e.g . hemolytic anemia ) require glucocorticosteroid treatment ( &gt; 0.5 mg/kg/day prednisone equivalent ) treatment Active central nervous system ( CNS ) leukemia , define unequivocal morphologic evidence lymphoblast cerebrospinal fluid ( CSF ) symptomatic CNS leukemia ( i.e . cranial nerve palsy significant neurologic dysfunction ) within 28 day treatment . Prophylactic intrathecal medication reason exclusion . Adult patient ( ≥18 year old ) follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Myocardial infarction ≤ 6months prior enrollment History clinically significant ventricular arrhythmia unexplained syncope , believe vasovagal nature due dehydration . History severe nonischemic cardiomyopathy EF ≤20 %</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic</keyword>
	<keyword>T-Lymphocytes ( EBV-CTLs )</keyword>
	<keyword>CD19 specific T-cells</keyword>
	<keyword>11-038</keyword>
</DOC>